Drug
Int 787
Int 787: highest development phase Phase 2, developed by Intercept Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Intercept Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| INT-787 NCT05639543 | Phase 2 | Alcohol Associated Hepatitis |
Latest
No recent events.
Follow Int 787 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.